Welcome to Sequence Card of Peptide


Details of CancerPDF entry with Sequence SSSYSKQFTSSTSYNRGDSTFES
Primary information
sequence IDSeq_7713
Peptide sequenceSSSYSKQFTSSTSYNRGDSTFES
CancerPDF_ID CancerPDF_ID12, CancerPDF_ID1029, CancerPDF_ID1281, CancerPDF_ID2399, CancerPDF_ID8516, CancerPDF_ID12723,
PMID16896061,16395409,21136997,21136997,23667664,27058005
Protein NameFibrinogen alpha chain,Fibrinogen alpha chain,Fibrinogen alpha,Fibrinogen alpha,Fibrinogen alpha,Fibrinogen alpha chain
UniprotKB Entry NameFIBA_HUMAN,FIBA_HUMAN,FIBA_HUMAN,FIBA_HUMAN,FIBA_HUMAN,FIBA_HUMAN
FluidSerum,Serum,Serum,Plasma,Serum,Serum
M/Z2553.01,2553.01,2552.09392,2552.0939,2552.09,2553.201
Charge1,1,1,1,1,NA
Mass (in Da)2553.09,NA,NA,NA,2554.6,NA
fdrNA,NA,NA,NA,NA,NA
Profiling TechniqueMALDI-TOF,MALDI-TOF,LC-MS,LC-MS,MALDI-TOF,MALDI-TOF
Peptide Identification techniqueQ/TOF MS/MS,Q/TOF/TOF and LC-MS/MS,LC-MS-MS/MS,LC-MS-MS/MS,FT-ICR MS/MS + nano-HPLC,LC-MS/MS
Quantification TechniqueNA,NA,LC-ESI-MS,LC-ESI-MS,NA,NA
Labelled/Label FreeLabel Free,Label Free,Label Free,Label Free,Label Free,Label Free
FDRNA,less than 1 “5,NA,NA,NA,NA
CancerPDF_ID CancerPDF_ID12, CancerPDF_ID1029, CancerPDF_ID1281, CancerPDF_ID2399, CancerPDF_ID8516, CancerPDF_ID12723,
p-Value1.00E-05,0.128,NA,NA,NA,"less than 0.001,0.221,0.943"
SoftwareMASCOT,MASCOT (v 2.0.04 for Windows),MASCOT(v. 2.2.01),MASCOT(v. 2.2.01),MASCOT,Proteome Discoverer
Length23,23,23,23,23,23
Cancer TypeMetastatic thyroid carcinomas,"Advanced Prostate, Breast and Bladder cancer",Colorectal cancer,Normal,"Breast cancer, Lung cancer, Rectal cancer",Breast cancer
DatabaseNCBI refseq Protein Database,NCBI refseq Protein Database,SwissProt Database,SwissProt Database,NA,SwissProt Database
ModificationNA,NA,NA,NA,NA,NA
Number of Patients40 metastatic thyroid carcinoma patients and 40 normal for training phase and 10 metastatic thyroid carcinoma and 10 normal individuals for independent validation,"Advanced prostate (n = 32), breast (n = 21), and bladder (n = 20) cancer, 33 healthy",30 patients and 30 healthy controls,27 healthy individuals,"Breast Cancer =84, lung cancer= 70, Rectal cancer = 30patients; 500 healthy"," 28 were diagnosed with Breast cancer, 27 remained cancer-free with BRCA carrier. Of the remaining patients, 39 were diagnosed with sporadic breast cancer (SBC), and 38 were healthy volunteers (WT)."
RegulationNA,"Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) = 1.35, 1.31 and 1.5 in prostate, bladder and breast cancer respectively",NA,NA,NA,"Upregulated with the fold change of 0.60 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 0.85, Upregulated in BC vs healthy with 0.992 fold change"
ValidationIndependent validation,Independent validation,Leave One out Cross validation,Leave One out Cross validation,NA,NA
Sensitivity95% on independent dataset,97.5% on independent validation dataset,NA,NA,NA,NA
Specificity95% on independent dataset,NA,NA,NA,NA,NA
AccuracyNA,97.5 % on validation dataset,NA,NA,NA,NA
Peptide AtlasNA
IEDB